Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
The 2013 declaration of obesity as a chronic disease and the 2021 approval of semaglutide are associated with increased use ...
So many options. So much noise. Here's what to know about GLP-1s now.
Japan is one of the world's most important pharmaceutical markets after the US and Europe.Neupharma’s team has extensive experience in developing and successfully commercialising orphan drugs as well ...
Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.
This important study analyzed the impact of amino acid homorepeats on protein expression and solubility in yeast and E. coli. The authors provided convincing evidence that hydrophobic and positively ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results